CN101759751A - Ginsenoside Rg 1 containing ginsenoside Re impurity - Google Patents
Ginsenoside Rg 1 containing ginsenoside Re impurity Download PDFInfo
- Publication number
- CN101759751A CN101759751A CN200810227642A CN200810227642A CN101759751A CN 101759751 A CN101759751 A CN 101759751A CN 200810227642 A CN200810227642 A CN 200810227642A CN 200810227642 A CN200810227642 A CN 200810227642A CN 101759751 A CN101759751 A CN 101759751A
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- elutriant
- filtrate
- ethanol elution
- equal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses standard effective ingredients of ginsenoside Rg 1, which is characterized by comprising the ginsenoside Rg 1 the content of which is more than or equal to 90% and less than 100%, wherein, the content of ginsenoside Re impurity is more than or equal to 0.05% and less than or equal to 7%; or the content of the ginsenoside Re impurity is more than or equal to 0.1% and less than or equal to 5%; or the content of the ginsenoside Re impurity is more than or equal to 0.5% and less than or equal to 5%. A pharmacological test proves that the standard effective ingredients of the invention have good pharmacological action, and the main ingredients have synergistic effect with the impurity, thus the ginsenoside Rg 1 can be taken as raw materials in pharmaceutical preparation.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicines, be specifically related to a kind of ginsenoside Rg of standard
1Effective constituent.
The invention reside in the middle pharmaceutically active ingredient that a kind of standard is provided, promptly contain the standard ginsenoside Rg of impurity ginsenoside Re
1Effective constituent.
Background technology
Middle pharmaceutically active ingredient is basic substance of its performance drug action, the comprehensive quality control of clear and system of curative effect material is the key and the core of the modernization of Chinese medicine, the every impurity greater than 0.1% of human drug legislation technology international coordination meeting regulation all should be controlled, the curative effect material and the impurity research of Chinese medicine is clear, could ensure its quality homogeneous, stable curative effect, safety is controlled, become standard active ingredient, be prepared into medicine as bulk drug, after listing, as when untoward reaction or side effect take place, can effectively follow the trail of root, has trackability, effectively impurity or synergy impurity should quantitatively be controlled, invalid impurity should carry out content and limit, poisonous impurity or detrimental impurity should further be removed, perhaps content is limited to harmless scope (such as less than 10PPM), therefore, impurity in the centering pharmaceutically active ingredient carries out deep research, has profound significance, help the modernization of Chinese medicine, help Chinese medicine to go to the world, help the healthy of the mankind more.
The ginsenoside Rg
1Have great pharmacological effects, have good patent medicine DEVELOPMENT PROSPECT, but these work are in initial period, the ginsenoside Rg
1Being developed to the medicine that is used for human medical use, also needing to do a lot of work, for example its relative substance is carried out deep analysis, is exactly one of major tasks of a lot of medical workers.
In sum, obtaining the ginsenoside Rg
1On the basis of effective constituent, study, obtain standardized effective constituent, have great significance at its impurity impurity that particularly content is bigger.
Summary of the invention
Our scientific research personnel is at total saponins such as the genseng of different sources, pseudo-ginseng, Radix Panacis Quinquefoliis, and " content is greater than 90% ginsenoside Rg preparing
1" the basis on, again by performing creative labour, proved conclusively the ginsenoside Rg
1In the effective constituent content bigger impurity be the ginsenoside Re, obtain the ginsenoside Rg
1Standard active ingredient, i.e. ginsenoside Rg
1Content is more than or equal to 90% and less than 100%, and foreign matter content is greater than 0 and smaller or equal to 10%, and impurity comprises the ginsenoside Re, and wherein the content of impurity ginsenoside Re is more than or equal to 0.05% and smaller or equal to 7%.This standardized ginsenoside Rg
1Effective constituent, can be directly as medicine material in market sale, the preparation raw material that also can be used as the medicament preparation uses, and like this, has both helped the stdn of Chinese medicine material, helps the standardization that Chinese medicine preparation is produced again; Simultaneously, our scientific research personnel is also at the ginsenoside Rg
1Extraction and purification process study: adopting Amberlyst process, is raw material with the total saponins, separates obtaining the ginsenoside Rg
1Crude product by the organic solvent extraction method, obtains the ginsenoside Rg again
1, this processing method is easy, can realize suitability for industrialized production, the ginsenoside Rg who obtains
1Cost is lower, its content and impurity is analyzed the ginsenoside Rg
1Content is more than or equal to 90%, and ginsenoside Re's content meets the ginsenoside Rg smaller or equal to 7% in the impurity
1The requirement of standard active ingredient.
The present invention is achieved through the following technical solutions.
The invention reside in the ginsenoside Rg that a kind of standard is provided
1, i.e. the middle pharmaceutically active ingredient of standard: ginsenoside Rg
1Content is more than or equal to 90%, and impurity is determined and quantitatively control; Standard ginsenoside Rg of the present invention
1Effective constituent can be used as the pharmaceutical preparation bulk drug and uses, on the basis that meets the pharmaceutical preparation requirement, and the ginsenoside Rg of preparation
1Pharmaceutical preparation can be used for the treatment of human body diseases.
The ginsenoside Rg of standard of the present invention
1Effective constituent is:
A kind of ginsenoside Rg
1, the ginsenoside Rg
1Content is more than or equal to 90% and less than 100%, and foreign matter content is greater than 0 and smaller or equal to 10%, and impurity comprises the ginsenoside Re, and wherein the content of impurity ginsenoside Re is more than or equal to 0.05% and smaller or equal to 7%.
Wherein the content of impurity ginsenoside Re is more than or equal to 0.1% and smaller or equal to 5%.
Wherein the content of impurity ginsenoside Re is more than or equal to 0.5% and smaller or equal to 5%.
The ginsenoside Re is the big impurity of content in the impurity in the above-mentioned standard active ingredient, by scientific experiment it is separated, and determines its structure by serial experiment again.
Above-mentioned standard active ingredient can be by genseng, pseudo-ginseng, Radix Panacis Quinquefolii, Vietnam's genseng, rhizome of Japanese Ginseng, obtain total saponins in the root of plants such as Curcurbitaceae gynostemma pentaphyllum genus gynostemma pentaphylla, edge fruit gynostemma pentaphylla, stem, leaf, the bud, carrying out purifying through the high performance liquid chromatography preparation method again obtains, also can carry out monomer separation by silica gel column chromatography, high performance liquid chromatography control terminal point obtains, or the like;
The above-mentioned standard ginsenoside Rg of the application
1Effective constituent also can be obtained by following method:
Get pseudo-ginseng, genseng, Radix Panacis Quinquefolii or gynostemma pentaphylla and extract the total saponins that obtains, total saponins is dissolved in water, and filters, and filtrate is by nonpolar or low-pole macroporous adsorptive resins, washing, elutriant discards, and the 20%-60% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, and filtrate is by nonpolar or low-pole macroporous adsorptive resins, washing, elutriant discards, and uses the 10%-50% ethanol elution again, and elutriant discards, use the 20%-60% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Perhaps: get pseudo-ginseng, genseng, Radix Panacis Quinquefolii or gynostemma pentaphylla and extract the total saponins that obtains, total saponins is dissolved in water; Lysate filters, and filtrate is washed by nonpolar or low-pole macroporous adsorptive resins, and elutriant discards, and the 20%-60% ethanol elution is collected elutriant, and is concentrated, dry, obtains the ginsenoside Rg
1Crude product adds organic solvent extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Total saponins in the above-mentioned steps can directly be bought by market or prepare according to scientific and technical literature;
Described Radix Notoginseng total arasaponins can perhaps prepare (Wei Junxian, Chen Yegao, Cao Shuming, the research of pseudo-ginseng carpopodium saponin component, CHINA JOURNAL OF CHINESE MATERIA MEDICA, 1992,17 (9): 611-613 according to existing patent documentation or scientific and technical literature by commercially available purchase; Yang Chongren, kingdom swallow, 5 jewels, etc., the saponin component of pseudo-ginseng reed head, pharmacy circular, 1985,20 (6): 337-338; Dong Aling, Zheng Junhua, fruit Dean, etc., the method for from pseudo-ginseng, separating the trace ingredients arasaponin, CHINA JOURNAL OF CHINESE MATERIA MEDICA, 2002,27 (10): 793-794; Ou Lailiang, Shi Zuoqing, Shi Rongfu, etc., the epistasis macroporous adsorbent resin is to the separation and purification research of arasaponin, herbal medicine, 2003,34 (10): 905-907; Zhang Guande, adsorption resin method is measured pseudo-ginseng and the total saponin of preparation perhexiline thereof, herbal medicine, 1981,12 (11): 23-25).
Described macroporous resin column includes but not limited to HPD-100, HPD-100A, HPD-300, HPD-400, HPD-400A, HPD-450, D101,1300-I, 1400 or AB-8.
Described organic solvent includes but not limited to one or more in ethyl acetate, acetone, propyl carbinol, ethanol, the methyl alcohol.
Above-mentioned ginsenoside Rg
1Pharmaceutical preparation for the unitary dose of active substance preparation.
Above-mentioned ginsenoside Rg
1Be the pharmaceutical preparation of active substance preparation, wherein unitary dose is 10mg-4000mg.
Above-mentioned ginsenoside Rg
1Treat and/or prevent application in cardiovascular and cerebrovascular diseases, tumour, shock, the hypomnesis medicine in preparation.
Beneficial technical effects of the present invention:
1, ginsenoside Rg
1The stdn of effective constituent can be used as bulk drug and carries out formulation preparation, after the medicine listing, has retrospective when untoward reaction or side effect take place.
2, genseng saponin(e Rg of the present invention
1Main component and impurity ginsenoside Re have collaborative pharmacological action in the effective constituent.
3, with the ginsenoside Rg
1The effective constituent stdn, the impurity that is about to the big impurity of content belongs to, and can be used as medicine material and uses, and helps modernization, the internationalization of Chinese medicine.
Though 4, contain purity in the prior art near 100% ginsenoside Rg
1Monomer, but like this raw material can't become medicine, its preparation technology's complexity causes can't suitability for industrialized production; It involves great expense and causes the price behind the patent medicine that the patient can't be accepted; Its yield is hanged down and has been caused wasting a large amount of limited resources very much; And the present invention prepares ginsenoside Rg1's standard active ingredient is on the basis of the total saponins that the different places of production, different methods obtain, employing is easy to suitability for industrialized production, technology is simple, cost is low, yield is high processing method prepares, saved resource, the drug price that is prepared into can make the patient accept.
One, ginsenoside Rg
1Content assaying method and detected result
The ginsenoside Rg
1Content assaying method can adopt ultraviolet spectrophotometry etc., also can measure according to prior art (such as the detection method of the ginsenoside of pharmacopeia in 2005 record), also can measure by the method that includes but not limited to following record:
Experimental technique: adopt high performance liquid chromatography to carry out assay.
Chromatographic column: C
18Reverse-phase chromatographic column; Chromatographic condition and system suitability experiment: with the octadecylsilane chemically bonded silica is weighting agent; Flow velocity 1.0ml/min; 25 ℃ of column temperatures; Detect wavelength 203nm; Number of theoretical plate is by the ginsenoside Rg
1Meter should be not less than 2500; With water: acetonitrile is a moving phase, carries out gradient elution by following condition of gradient elution, moves 60 minutes;
In the time of 0-40 minute, the ratio of water reduces to 50% by 80%, and the ratio of acetonitrile rises to 50% by 20%; In the time of 40-43 minute, the ratio of water reduces to 20% by 50%, and the ratio of acetonitrile rises to 80% by 50%; In the time of 43-48 minute, keeping the ratio of water is 20%, and keeping the ratio of acetonitrile is 80%; In the time of 48-50 minute, the water ratio rises to 80% by 20%, and the ratio of acetonitrile reduces to 20% by 80%; 50-60 minute keeps the ratio of water is 20%, the ratio 80% of acetonitrile;
The preparation of reference substance solution: precision takes by weighing the ginsenoside Rg
1Reference substance adds dissolve with methanol and shakes up in volumetric flask, and is diluted to scale;
The preparation of need testing solution: precision takes by weighing sample and adds dissolve with methanol in the volumetric flask and shake up, and is diluted to scale;
Assay method: accurate respectively absorption reference substance solution and need testing solution respectively inject liquid chromatograph, adopt by external standard method with calculated by peak area, promptly.
Annotate: genseng saponin(e Rg of the present invention
1Reference substance is the statutory standards product, buys from Chinese pharmaceutical biological product and identifies institute.
Standard ginsenoside Rg of the present invention
1Content of effective measurement result and check and analysis:
Get standard ginsenoside Rg of the present invention
1Effective constituent, carry out the check and analysis experimental result according to above-mentioned experimental technique and see Table 1:
Table 1 ginsenoside Rg
1The sample determination result
Experiment conclusion: show standard ginsenoside Rg of the present invention by above-mentioned experiment
1In the effective constituent, the ginsenoside Rg
1Content is more than or equal to 90% and less than 100%, and wherein the content of impurity ginsenoside Re is more than or equal to 0.05% and smaller or equal to 7%; Wherein the content of impurity ginsenoside Re is more than or equal to 0.1% and smaller or equal to 5%; Wherein the content of impurity ginsenoside Re is more than or equal to 0.5% and smaller or equal to 5%.
Two, ginsenoside Re's structural identification data
Get standard ginsenoside Rg of the present invention
1Effective constituent is separated through silica gel column chromatography, and in conjunction with the control of high performance liquid chromatography liquid method, the impurity that content is bigger separates, and obtains the impurity monomer, carries out structural identification, and the conclusive evidence data is as follows:
IRv
max KBrcm
-1：3450(-OH)，1640(C＝C)。
UVλ
max MeOHnm：202
Ginsenoside Re's carbon spectrum ownership:
13C-NMR(C
5D
5N)δppm：39.5(C-1)，27.8(C-2)，78.8(C-3)，40.1(C-4)，60.9(C-5)，74.8(C-6)，46.0(C-7)，41.3(C-8)，49.7(C-9)，39.8(C-10)，30.9(C-11)，70.3(C-12)，49.2(C-13)，51.5(C-14)，31.0(C-15)，26.7(C-16)，51.8(C-17)，17.6(C-18)，17.6(C-19)，83.4(C-20)，22.4(C-21)，36.1(C-22)，23.3(C-23)，126.1(C-24)，131.0(C-25)，25.8(C-26)，17.8(C-27)，32.2(C-28)，17.4(C-29)，17.3(C-30)，101.9(C-1′)，79.2(C-2′)，78.2(C-3′)，72.7(C-4′)，78.2(C-5′)，63.2(C-6′)，101.9(C-1)，72.5(C-2″)，72.4(C-3″)，74.2(C-4″)，69.5(C-5″)，18.8(C-6″)，98.3(C-1″″)，75.2(C-2″′)，79.4(C-3″′)，71.7(C-4″′)，78.5(C-5″′)，62.9(C-6″′)。
Ginsenoside Re's hydrogen spectrum ownership:
1H-NMR (C
5D
5N) δ ppm:0.95,0.97,1.18,1.36,1.58,1.61,1.62,2.09 (3Heach, H-18,19,21,26,27,28,29,30-CH
3), 1.75 (3H, d, j=6.1Hz, H-6 "), 5.15 (1H, d, j=7.8Hz, sugared terminal hydrogens), 5.24 (1H, d, j=6.7Hz, sugared terminal hydrogens) 5.59 (1H, s, H-24).
Experiment conclusion: show that by above-mentioned experiment one of big impurity of content of the present invention is the ginsenoside Re.
Three, pharmacological evaluation
The influence of 1 pair of mouse brain ischemic of experiment (the ligation bilateral common carotid arteries merges the blood pressure drops method)
Laboratory animal: KM small white mouse, 23 ± 2g.
Experiment medicine: genseng saponin(e Rg of the present invention
1Effective constituent (standard that meets standard active ingredient of the present invention); The ginsenoside Rg
1Monomer (content is 99.5%).
Experiment reagent: urethane etc.
Experimental technique: with the mouse random packet: experiment contrast group group, ginsenoside Rg
1Set of monomers, genseng saponin(e Rg of the present invention
1The effective constituent group; The tail intravenously administrable, dosage 0.40mg/kg.After the administration 5 days, in last administration 1 hour, press 1.0g/kg with 12% urethane, behind the intraperitoneal injection of anesthesia, it is fixing that mouse is lain on the back, through neck median incision, separate bilateral carotid arteries and cover with " 0 " number silk thread, after bilateral carotid arteries ligation simultaneously blocking-up and determining that no blood passes through, cut off silk thread perfusion 10min behind the 30min, after blocking 30min once more, decontrol line, make blood flow logical again.In the time of blocking-up, cut off bloodletting at distance tail point 1.5cm place, the bloodletting amount is hanged down perfusion less than 6% of body weight to cause full brain, and hemostasis is coagulated in the bloodletting after heat.Art finishes intraperitoneal injection of saline 1ml.Before and after ligation, dynamic observe and write down ischemic 30min and pour into the 90min electroencephalogram again and change.It is standard that the enforcement ligation is the bar straight line with electroencephalogram.Trachea cannula connects the animalcule respirator, carries out artificial ventilation's (air flow 20ml/kg, frequency 70-80 time/minute).
(1) adopts scoring of palsy index and neurological symptom score standard.
The scoring of palsy index: total points 25 minutes, 0～3 is " symptom group "; 3～9 are divided into " middle groups ", have damage; Obviously diminished wound in＞10 minutes.Hair is dirty and messy to tremble: 1 minute, hypokinesis or blunt: 1 minute, the ear hypesthesia: 3 minutes, a perk: 3 minutes, the hind leg abduction was " eight " word: 3 minutes, and ptosis: 1 minute, turn-take: 3 minutes, faint from fear or the outburst motion: 3 minutes, extremely weak: 6 minutes.
Neurological symptom score standard: total points 10 minutes, 0 minute normal, 1～3 fen minor injury, 4～6 fens moderate lesion, 7～10 fens major injuries.Spontaneous probing into arranged: 0 minute, can walk about during stimulation: 1 minute, normal gait: 0 minute, ataxia: 1 minute, creep: 2 minutes, no gait: 3 minutes; Can take food: 0 minute, can not take food: 1 minute; Can drink water: 0 minute, can not drink water: 1 minute; Pain stimulation is removable: 0 minute, and only head or trunk motion: 1 minute, limbs retraction or reactionless: 2 minutes.
(2) brain water content is measured
Get full brain and isolate pallium, claim in 100 ℃ of baking boxs, to dry 24h after its weight in wet base, dry continuously 3 times, get its mean value calculation brain water content.
Experimental result: the results are shown in Table 4.
The influence of table 4 pair mouse brain ischemic
Annotate: compare with the experiment contrast group
*P＜0.01; Compare #P＜0.05 with the positive drug group.
The comparison of 2 pairs of rats'liver tumor suppression of experiment
Laboratory animal: rat, 150g-180g, male and female are regardless of.
Experiment medicine: genseng saponin(e Rg of the present invention
1Effective constituent (standard of compound standard active ingredient of the present invention); The ginsenoside Rg
1Monomer (content is 99.5%).
Experiment reagent: vetanarcol.
Laboratory apparatus: silver brain clip; Survey meter.
Experimental technique: get rat and be divided into physiological saline group, the application's standard ginsenoside Rg
1Effective constituent group, ginsenoside Rg
1Set of monomers is made W
256Liver in inoculation, inoculate after 7 days, press the dosage intraperitoneal injection of anesthesia of 35mg/kg with vetanarcol, fixing, cutting open the belly exposes liver, tumor surface maximum diameter (a) and path (b) are pressed (a * b on the measurement liver
2)/2=V (gross tumor volume).Separate stomach, arteria duodenalis, arteria hepatica communis and proper hepatic artery, the ligation stomach, the arteria duodenalis far-end, with silver brain clip blocking-up arteria hepatica communis, in sending into proper hepatic artery again at the gastroduodenal artery upper cut and after inserting external diameter 0.3mm conduit under the operating loupe, inject respectively by experiment grouping then and be subjected to the reagent thing (dosage is identical, administration group dosage is 0.25mg/kg, physiological saline groups etc. are held inequality) postoperative tube drawing ligation gastroduodenal artery, decontrol the arteria hepatica communis silver brain clip, sew up the incision again, place animal housing to wait to revive rat, continue breeding observing, performed the operation back 8 days, and detected gross tumor volume by last method.
Experimental result sees Table 5:
Table 5 is respectively organized preparation to the rejection ratio of tumour
Annotate: compare with the physiological saline group
*P＜0.01; Compare #P＜0.05 with positive controls
Experiment brief summary: show that by above-mentioned experiment effective constituent group of the present invention compares the ginsenoside Rg
1Set of monomers relatively has significant difference (P＜0.05), further specifies ginsenoside Rg in the effective constituent of the present invention
1Principal constituent and impurity ginsenoside Re have synergy, prove absolutely that standard active ingredient of the present invention has scientific meaning.
Annotate: genseng saponin(e Rg of the present invention
1Standard active ingredient is carried out pharmacological experiments such as cardiovascular disorder, anti-ageing, hypomnesis, antishock, and it is identical with above-mentioned experiment conclusion to obtain experiment conclusion.
Four, dose screening experiment-to the provide protection of anesthetized rat myocardial ischemia-reperfusion injury
Laboratory animal: healthy SD rat, body weight 240-260g.
Experiment medicine: physiological saline; Standard ginsenoside Rg of the present invention
1Effective constituent (meeting the qualification of standard active ingredient of the present invention) to impurity ginsenoside Re.
Experiment reagent: 20% urethane is pressed; The tincture of iodine; Test kit; 1%TTC.
Laboratory apparatus: respirator; Electrocardiograph; The ophthalmology tweezer; Automatic clinical chemistry analyzer; Digital camera.
Experimental technique: with the rat random packet: model group, genseng saponin(e Rg of the present invention
1The various dose group.Place the pre-raising of equivalent environment 2 days, free diet.After pre-raising finishes, experimentize, animal is weighed, and 20% urethane is pressed the 0.6ml/100g abdominal injection, after treating that anesthesia is satisfied, lie on the back and be fixed on the mouse plate, trachea cannula connects respirator, by 10～12ml Tidal volume, 70 times/minute frequency is exhaled, and continuous positive pressure breathing is inhaled: exhale than being 1: 1.Adjust respiration parameter according to the respiratory rate and the degree of depth.Connect electrocardiograph subsequently, survey normal ECG.Cut off front field of operation hair, iodine disinfection, cut off skin, subcutis, front muscle and manadesma 3～4cm, it is long to separate intercostal muscle 3cm with the 18# vascular clamp along the 3rd intercostal passivity, open thoracic cavity and pericardium, recording ecg, strut 3,4 ribs, refer to hold thoracic cavity, rat right side with left hand four, the assistant upwards pushes away thymus gland with the ophthalmology tweezer, finds ligation sign blood vessel great cardiac vein between left auricle of heart and pulmonary conus, the 2mm place is with there not being wound roundlet pin band 6-0 silk thread threading below left auricle of heart, depth of needle is 1～1.5mm, wide 2～3mm, recording ecg behind the threading, give corresponding soup through the tail vein, recording ecg behind the administration 10min, and with one the band groove little plastics pipe pad at the ligation position, the ligation thereon of two rear line heads.At once recording ecg after the ligation is cyanosis or the II S-T section back of a bow that leads with left chamber antetheca and upwards raises greater than 0.1mv and be that ligation successfully indicates (it is superseded that the S-T section does not have the changer) more than the lasting 0.5h.10min recording ecg is once more cut off ligature behind the ligation 30min after the ligation, realizes perfusion again, and record pours into electrocardiogram(ECG at once again, removes in the thoracic cavity layer-by-layer suture wall of the chest behind the hematocele, removes respirator, animal recovery autonomous respiration, and incision of trachea does not process.Irritate again at once, 10min, 20min, 40min, 1h, 2h, 3h recording ecg respectively.Irritated again 3 hours, through abdominal aortic blood, 4000rpm is centrifugal, and 10min gets serum, adopt automatic clinical chemistry analyzer to detect LDH, CK and CK-MB activity, and adopt the corresponding reagent box to detect SOD in serum, MDA (above index specifically detects step and sees specification sheets for details), dissection is cored dirty, the residual blood of ice physiological saline flush away, cut off atrium and right ventricle, put into refrigerator and cooled immediately and freeze.With heart after refrigerator and cooled is frozen 10min, from the apex of the heart entad the parallel coronary sulcus direction in the end 5 of equal thickness are cut in left chamber, put into the 1%TTC dye liquor, 37 ℃ of dyeing 10min, the necrotic area is not a garnet, the necrotic area is canescence.Digital camera is taken pictures.Weighed respectively in necrotic area and non-necrotic area, calculate the per-cent that the necrotic area accounts for left ventricular mass, i.e. infarction size.
Experimental result: The selection result sees Table 6.
The influence of myocardial ischemia myocardial infarct size (%) due to table 6 pair ligation/logical again rat ramus descendens anterior arteriae coronariae sinistrae
Annotate: compare with model group,
*P＜0.01,
*P＜0.05.
Experiment conclusion: show genseng saponin(e Rg of the present invention by the dose screening experiment
1Increasing drug action with dosage changes; Through us dose screening experiment and toxicity test, determine genseng saponin(e Rg of the present invention
1Unitary dose be 10mg-4000mg (dosage toxic reaction occurs greater than 4000mg, does not almost have drug action less than 10mg).
Five, embodiment
Embodiment 1
A kind of ginsenoside Rg
1, the ginsenoside Rg
1Content 93.01%, impurity ginsenoside Re content 6.97%.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 2
A kind of ginsenoside Rg
1, the ginsenoside Rg
1Content 99.89%, impurity ginsenoside Re content 0.05%.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 3
A kind of ginsenoside Rg
1, the ginsenoside Rg
1Content 94.72%, impurity ginsenoside Re content 5.00%.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 4
A kind of ginsenoside Rg
1, the ginsenoside Rg
1Content 98.95%, the content 0.10% of impurity ginsenoside Re.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 5
A kind of ginsenoside Rg
1, the ginsenoside Rg
1Content 92.92%, the content 6.50% of impurity ginsenoside Re.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 6
A kind of ginsenoside Rg
1, the ginsenoside Rg
1Content 99.85%, the content 0.09% of impurity ginsenoside Re.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 7
A kind of ginsenoside Rg
1, the ginsenoside Rg
1Content 96.29%, the content 3.54% of impurity ginsenoside Re.Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 8
A kind of ginsenoside Rg
1, the ginsenoside Rg
1Content 98.17%, the content 0.96% of impurity ginsenoside Re.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 9
A kind of ginsenoside Rg
1, the ginsenoside Rg
1Content 94.24%, the content 5.68% of impurity ginsenoside Re.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 10
A kind of ginsenoside Rg
1, the ginsenoside Rg
1Content 95.84%, the content 4.11% of impurity ginsenoside Re.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
The ginsenoside Re is that content is one of bigger in the impurity in the foregoing description 1-10 standard active ingredient, by scientific experiment it is separated, and determines its structure by serial experiment again.
The foregoing description 1-10 standard active ingredient can be by obtaining total saponins in the root of different places of production pseudo-ginseng, genseng, Radix Panacis Quinquefolii or gynostemma pentaphylla, stem, leaf, the bud, carrying out purifying through the high performance liquid chromatography preparation method again obtains, also can carry out monomer separation by silica gel column chromatography, high performance liquid chromatography control terminal point obtains, or the like; Also can prepare by following method:
Embodiment 11
Get genseng and extract the Radix Ginseng total saponins obtain and be dissolved in water, filter, filtrate is by the HPD-400A macroporous adsorptive resins, washing, elutriant discards, and 20% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-400A macroporous adsorptive resins, and elutriant discards, use 10% ethanol elution again, elutriant discards, and uses 20% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent ethyl acetate, acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Perhaps: get genseng and extract the total saponins that obtains, total saponins is dissolved in water; Lysate filters, and filtrate is washed by the HPD-400A macroporous adsorptive resins, and elutriant discards, and 20% ethanol elution is collected elutriant, and is concentrated, dry, obtains the ginsenoside Rg
1Crude product adds organic solvent ethyl acetate, acetone extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
The method that genseng extracts total saponins is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside is as Rg
1Medicine material can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 12
Get Radix Panacis Quinquefolii and extract the American ginseng total saponins obtain and be dissolved in water, filter, filtrate is by the HPD-400 macroporous adsorptive resins, washing, elutriant discards, and 60% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-400 macroporous adsorptive resins, and elutriant discards, use 50% ethanol elution again, elutriant discards, and uses 60% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent ethyl acetate, acetone, propyl carbinol heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Perhaps: get Radix Panacis Quinquefolii and extract the total saponins that obtains, total saponins is dissolved in water; Lysate filters, and filtrate is washed by the HPD-400 macroporous adsorptive resins, and elutriant discards, and the 20%-60% ethanol elution is collected elutriant, and is concentrated, dry, obtains the ginsenoside Rg
1Crude product adds organic solvent extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described American ginseng total saponins extracting method is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 13
Get pseudo-ginseng and extract and to obtain total saponins and be dissolved in water, filter, filtrate is by the HPD-300 macroporous adsorptive resins, washing, elutriant discards, and 25% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-300 macroporous adsorptive resins, and elutriant discards, use 15% ethanol elution again, elutriant discards, and uses 25% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent propyl carbinol, alcohol heating reflux extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins extracting method is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 14
Get gynostemma pentaphylla and extract the total saponins obtain and be dissolved in water, filter, filtrate is by the HPD-450 macroporous adsorptive resins, washing, elutriant discards, and 55% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-450 macroporous adsorptive resins, and elutriant discards, use 45% ethanol elution again, elutriant discards, and uses 55% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent ethyl acetate, acetone, propyl carbinol, ethanol, methyl alcohol heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described extracting gypenosides can be led to the existing patent documentation of basis or scientific and technical literature is prepared.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 15
Get Radix Ginseng total saponins and be dissolved in water, filter, filtrate is washed by the HPD-100A macroporous adsorptive resins, elutriant discards, and 30% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-100A macroporous adsorptive resins, and elutriant discards, use 20% ethanol elution again, elutriant discards, and uses 30% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent propyl carbinol heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Ginseng total saponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 16
Get Radix Notoginseng total arasaponins and be dissolved in water, filter, filtrate is washed by the D101 macroporous adsorptive resins, elutriant discards, and 35% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the D101 macroporous adsorptive resins, and elutriant discards, use 25% ethanol elution again, elutriant discards, and uses 235% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone, methyl alcohol heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 17
Get Radix Ginseng total saponins and be dissolved in water, filter, filtrate is washed by the HPD-100A macroporous adsorptive resins, elutriant discards, and 40% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-100A macroporous adsorptive resins, and elutriant discards, use 30% ethanol elution again, elutriant discards, and uses 40% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent alcohol heating reflux and extracts, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Ginseng total saponins is by commercially available purchase.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 18
Get American ginseng total saponins and be dissolved in water, filter, filtrate is washed by the 1300-I macroporous adsorptive resins, elutriant discards, and 45% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the 1300-I macroporous adsorptive resins, and elutriant discards, use 35% ethanol elution again, elutriant discards, and uses 50% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described the West is given birth to total saponins and is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 19
Get pseudo-ginseng and extract the total saponins obtain and be dissolved in water, filter, filtrate is by the HPD-100 macroporous adsorptive resins, washing, elutriant discards, and 50% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-100 macroporous adsorptive resins, and elutriant discards, use 45% ethanol elution again, elutriant discards, and uses 55% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent ethyl acetate, acetone, methyl alcohol heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins extracting method prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 20
Get Radix Notoginseng total arasaponins and be dissolved in water, filter, filtrate is washed by 1400 macroporous adsorptive resins, elutriant discards, and 60% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by 1400 macroporous adsorptive resins, and elutriant discards, use 10% ethanol elution again, elutriant discards, and uses 30% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent ethyl acetate, methyl alcohol heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 21
Get pseudo-ginseng and extract and to obtain total saponins and be dissolved in water, filter, filtrate is by the AB-8 macroporous adsorptive resins, washing, elutriant discards, and 25% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the AB-8 macroporous adsorptive resins, and elutriant discards, use 40% ethanol elution again, elutriant discards, and uses 60% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins extracting method prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 22
Get genseng and extract and to obtain total saponins and be dissolved in water, filter, filtrate is by the AB-8 macroporous adsorptive resins, washing, elutriant discards, and 40% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the AB-8 macroporous adsorptive resins, and elutriant discards, use 30% ethanol elution again, elutriant discards, and uses 40% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Ginseng total saponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 23
Get Radix Notoginseng total arasaponins and be dissolved in water, filter, filtrate is washed by the HPD-100 macroporous adsorptive resins, elutriant discards, and 40% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-100 macroporous adsorptive resins, and elutriant discards, use 30% ethanol elution again, elutriant discards, and uses 40% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins according to existing patent documentation or scientific and technical literature prepare (Yang Chongren, kingdom swallow, 5 jewels, etc., the saponin component of pseudo-ginseng reed head, pharmacy circular, 1985,20 (6): 337-338; ).
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 24
Get American ginseng total saponins and be dissolved in water, filter, filtrate is washed by the AB-8 macroporous adsorptive resins, elutriant discards, and 35% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the AB-8 macroporous adsorptive resins, and elutriant discards, use 35% ethanol elution again, elutriant discards, and uses 55% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described American ginseng total saponins is by commercially available purchase.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 25
Get pseudo-ginseng and extract the Radix Notoginseng total arasaponins obtain and be dissolved in water, filter, filtrate is by the AB-8 macroporous adsorptive resins, washing, elutriant discards, and 20% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by 1400 macroporous adsorptive resins, and elutriant discards, use 15% ethanol elution again, elutriant discards, and uses 30% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins preparation method is prepared according to existing patent documentation or scientific and technical literature;
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 26
Get pseudo-ginseng and extract the Radix Notoginseng total arasaponins obtain and be dissolved in water, filter, filtrate is by 1400 macroporous adsorptive resins, washing, elutriant discards, and 55% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-100A macroporous adsorptive resins, and elutriant discards, use 50% ethanol elution again, elutriant discards, and uses 60% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Ginseng total saponins extracting method prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 27
Get Radix Panacis Quinquefolii and extract and to obtain total saponins and be dissolved in water, filter, filtrate is by the D101 macroporous adsorptive resins, washing, elutriant discards, and 50% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the 1300-I macroporous adsorptive resins, and elutriant discards, use 15% ethanol elution again, elutriant discards, and uses 30% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone, ethyl acetate heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described American ginseng total saponins extracting method prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 28
Get genseng and extract the total saponins obtain and be dissolved in water, filter, filtrate is by the D101 macroporous adsorptive resins, washing, elutriant discards, and 30% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the D101 macroporous adsorptive resins, and elutriant discards, use 45% ethanol elution again, elutriant discards, and uses 60% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone, ethyl acetate heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
The extracting method of described Radix Ginseng total saponins can lead to the existing patent documentation of basis or scientific and technical literature prepares.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 29
Get gynostemma total saponin and be dissolved in water, filter, filtrate is washed by the HPD-300 macroporous adsorptive resins, elutriant discards, and 40% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-300 macroporous adsorptive resins, and elutriant discards, use 30% ethanol elution again, elutriant discards, and uses 40% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described gynostemma total saponin prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 30
Get Radix Notoginseng total arasaponins and be dissolved in water, filter, filtrate is washed by the HPD-400 macroporous adsorptive resins, elutriant discards, and 40% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-450 macroporous adsorptive resins, and elutriant discards, use 30% ethanol elution again, elutriant discards, and uses 40% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 31
Get Radix Panacis Quinquefolii and extract and to obtain total saponins and be dissolved in water, filter, filtrate is by the HPD-400 macroporous adsorptive resins, washing, elutriant discards, and 40% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-400 macroporous adsorptive resins, and elutriant discards, use 30% ethanol elution again, elutriant discards, and uses 40% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described American ginseng total saponins extracting method prepares according to existing document.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 32
Get genseng and extract and to obtain total saponins and be dissolved in water, filter, filtrate is by the HPD-400 macroporous adsorptive resins, washing, elutriant discards, and 45% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-400 macroporous adsorptive resins, and elutriant discards, use 30% ethanol elution again, elutriant discards, and uses 40% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Ginseng total saponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 33
Get pseudo-ginseng and extract the total saponins obtain and be dissolved in water, filter, filtrate is by the HPD-100A macroporous adsorptive resins, washing, elutriant discards, and 35% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-100A macroporous adsorptive resins, and elutriant discards, use 25% ethanol elution again, elutriant discards, and uses 45% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins extracting method is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned Panax Notoginseng saponin R g
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 34
Get Radix Notoginseng total arasaponins and be dissolved in water, filter, filtrate is washed by the HPD-400 macroporous adsorptive resins, elutriant discards, and 45% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-400 macroporous adsorptive resins, and elutriant discards, use 25% ethanol elution again, elutriant discards, and uses 35% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside is as Rg
1Medicine material can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 35
Get pseudo-ginseng and extract and to obtain total saponins and be dissolved in water, filter, filtrate is by the HPD-450 macroporous adsorptive resins, washing, elutriant discards, and 40% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-450 macroporous adsorptive resins, and elutriant discards, use 30% ethanol elution again, elutriant discards, and uses 40% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins extracting method is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 36
Get pseudo-ginseng and extract and to obtain total saponins and be dissolved in water, filter, filtrate is by the 1300-I macroporous adsorptive resins, washing, elutriant discards, and 40% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the 1300-I macroporous adsorptive resins, and elutriant discards, use 30% ethanol elution again, elutriant discards, and uses 40% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 37
Get Radix Notoginseng total arasaponins and be dissolved in water, filter, filtrate is washed by the AB-8 macroporous adsorptive resins, elutriant discards, and 40% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the AB-8 macroporous adsorptive resins, and elutriant discards, use 30% ethanol elution again, elutriant discards, and uses 40% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside is as Rg
1Medicine material can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 38
Get Radix Notoginseng total arasaponins and be dissolved in water, filter, filtrate is washed by the D101 macroporous adsorptive resins, elutriant discards, and 40% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the AB-8 macroporous adsorptive resins, and elutriant discards, use 30% ethanol elution again, elutriant discards, and uses 40% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent-acetone heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins is by commercially available purchase.
Above-mentioned ginsenoside is as Rg
1Medicine material can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 39
Get pseudo-ginseng and extract the Radix Notoginseng total arasaponins obtain and be dissolved in water, filter, filtrate is by the HPD-400A macroporous adsorptive resins, washing, elutriant discards, 20% ethanol elution is collected elutriant, concentrate, dry, the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
The method that pseudo-ginseng is extracted total saponins is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside is as Rg
1Medicine material can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 40
Get genseng and extract the total saponins obtain and be dissolved in water, filter, filtrate is by the HPD-400 macroporous adsorptive resins, washing, elutriant discards, 60% ethanol elution is collected elutriant, concentrate, dry, the ginsenoside Rg
1Crude product adds the organic solvent butanone extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Ginseng total saponins extracting method is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 41
Get Radix Panacis Quinquefolii and extract and to obtain total saponins and be dissolved in water, filter, filtrate is by the HPD-300 macroporous adsorptive resins, washing, elutriant discards, 25% ethanol elution is collected elutriant, concentrate, dry, the ginsenoside Rg
1Crude product adds the organic solvent butanone extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described American ginseng total saponins extracting method is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 42
Get pseudo-ginseng and extract the total saponins obtain and be dissolved in water, filter, filtrate is by the HPD-450 macroporous adsorptive resins, washing, elutriant discards, 55% ethanol elution is collected elutriant, concentrate, dry, the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
The extracting method of described Radix Notoginseng total arasaponins can lead to the existing patent documentation of basis or scientific and technical literature is prepared.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 43
Get gynostemma total saponin and be dissolved in water, filter, filtrate is by the HPD-100A macroporous adsorptive resins, washing, elutriant discards, 30% ethanol elution is collected elutriant, concentrates, dry, do the ginsenoside Rg
1Crude product adds the organic solvent butanone extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described gynostemma total saponin prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 44
Get Radix Ginseng total saponins and be dissolved in water, filtration, filtrate is washed by the D101 macroporous adsorptive resins, and elutriant discards, and 35% ethanol elution is collected elutriant, and is concentrated, dry, gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Ginseng total saponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 45
Get American ginseng total saponins and be dissolved in water, filtration, filtrate is washed by the HPD-100A macroporous adsorptive resins, and elutriant discards, and 40% ethanol elution is collected elutriant, and is concentrated, dry, gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described American ginseng total saponins is by commercially available purchase.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 46
Get Radix Notoginseng total arasaponins and be dissolved in water, filtration, filtrate is washed by the 1300-I macroporous adsorptive resins, and elutriant discards, and 45% ethanol elution is collected elutriant, and is concentrated, dry, gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins according to existing patent documentation or scientific and technical literature prepare (Yang Chongren, kingdom swallow, 5 jewels, etc., the saponin component of pseudo-ginseng reed head, pharmacy circular, 1985,20 (6): 337-338).
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 47
Get genseng and extract the total saponins obtain and be dissolved in water, filter, filtrate is by the HPD-100 macroporous adsorptive resins, washing, elutriant discards, 50% ethanol elution is collected elutriant, concentrate, dry, the ginsenoside Rg
1Crude product adds organic solvent ethyl acetate, methanol extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Ginseng total saponins extracting method prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 48
Get American ginseng total saponins and be dissolved in water, filter, filtrate is washed by 1400 macroporous adsorptive resins, elutriant discards, and 60% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by 1400 macroporous adsorptive resins, and elutriant discards, use 10% ethanol elution again, elutriant discards, and uses 30% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent butanone extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described American ginseng total saponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 49
Get pseudo-ginseng and extract and to obtain total saponins and be dissolved in water, filter, filtrate is by the AB-8 macroporous adsorptive resins, washing, elutriant discards, and 25% ethanol elution is collected elutriant, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by non-AB-8 macroporous adsorptive resins, and elutriant discards, use 40% ethanol elution again, elutriant discards, and uses 60% ethanol elution again, collect elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins extracting method prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 50
Get pseudo-ginseng and extract and to obtain total saponins and be dissolved in water, filter, filtrate is by the AB-8 macroporous adsorptive resins, washing, elutriant discards, 40% ethanol elution is collected elutriant, concentrates, dry, do the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
The selection of macroporous resin includes but not limited to the above-mentioned type of lifting in the foregoing description, also can use and use other nonpolar or low-pole macroporous adsorbent resin in the prior art.
The foregoing description 10-50 obtains the ginsenoside Rg
1In the effective constituent, the ginsenoside Rg
1Content is more than or equal to 90% and less than 100%, and the content of impurity ginsenoside Re is more than or equal to 0.05% and smaller or equal to 7%; Perhaps the content of impurity ginsenoside Re is more than or equal to 0.1% and smaller or equal to 5%; Perhaps the content of impurity ginsenoside Re is more than or equal to 0.5% and smaller or equal to 5%;
The ginsenoside Rg of the foregoing description 1-50
1Be the pharmaceutical preparation of active substance preparation, wherein unitary dose is 10mg-4000mg.
Above-mentioned ginsenoside Rg
1Treat and/or prevent application in cardiovascular and cerebrovascular diseases, shock, tumour, aging, the hypomnesis medicine in preparation.
Above-mentioned genseng, pseudo-ginseng, Radix Panacis Quinquefolii, gynostemma pentaphylla can be root, stem, leaf, the bud in the different places of production.
Annotate: the present invention's concrete technical scheme required for protection is not limited to the concrete combination of the expressed technical scheme of the foregoing description.
Claims (9)
1. ginsenoside Rg
1, it is characterized in that the ginsenoside Rg
1Content is more than or equal to 90% and less than 100%, and foreign matter content is greater than 0 and smaller or equal to 10%, and impurity comprises the ginsenoside Re, and wherein the content of impurity ginsenoside Re is more than or equal to 0.05% and smaller or equal to 7%.
2. a kind of ginsenoside Rg according to claim 1
1, wherein the content of impurity ginsenoside Re is more than or equal to 0.1% and smaller or equal to 5%.
3. a kind of ginsenoside Rg according to claim 1
1, wherein the content of impurity ginsenoside Re is more than or equal to 0.5% and smaller or equal to 5%.
4. according to each described a kind of ginsenoside Rg of claim 1-3
1, its preparation method is: get pseudo-ginseng, genseng, Radix Panacis Quinquefolii or gynostemma pentaphylla and extract the total saponins that obtains, total saponins is dissolved in water, filter, filtrate is washed by nonpolar or low-pole macroporous adsorptive resins, and elutriant discards, the 20%-60% ethanol elution, collect elutriant, concentrated, dry, dry thing is dissolved in water, filter, filtrate is washed by nonpolar or low-pole macroporous adsorptive resins, and elutriant discards, use the 10%-50% ethanol elution, elutriant discards, and uses the 20%-60% ethanol elution again, collects elutriant, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent heating and refluxing extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Perhaps: get pseudo-ginseng, genseng, Radix Panacis Quinquefolii or gynostemma pentaphylla and extract the total saponins that obtains, total saponins is dissolved in water; Lysate filters, and filtrate is washed by nonpolar or low-pole macroporous adsorptive resins, and elutriant discards, and the 20%-60% ethanol elution is collected elutriant, and is concentrated, dry, obtains the ginsenoside Rg
1Crude product adds organic solvent extraction, and extracting solution filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
5. according to each described a kind of ginsenoside Rg of claim 1-3
1Pharmaceutical preparation for the unitary dose of active substance preparation.
6. a kind of ginsenoside Rg according to claim 4
1, wherein nonpolar the or low-pole macroporous resin described in the preparation method is HPD-100, HPD-100A, HPD-300, HPD-400, HPD-400A, HPD-450, D101,1300-I, 1400 or AB-8.
7. a kind of ginsenoside Rg according to claim 4
1, wherein the organic solvent described in the preparation method is one or more in ethyl acetate, acetone, propyl carbinol, ethanol, the methyl alcohol.
8. a kind of ginsenoside Rg according to claim 5
1Be the pharmaceutical preparation of active substance preparation, wherein unitary dose is 10mg-4000mg.
9. according to each described a kind of ginsenoside Rg of claim 1-3
1Treat and/or prevent application in cardiovascular and cerebrovascular diseases, tumour, shock, the hypomnesis medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810227642A CN101759751A (en) | 2008-11-28 | 2008-11-28 | Ginsenoside Rg 1 containing ginsenoside Re impurity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810227642A CN101759751A (en) | 2008-11-28 | 2008-11-28 | Ginsenoside Rg 1 containing ginsenoside Re impurity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101759751A true CN101759751A (en) | 2010-06-30 |
Family
ID=42491147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810227642A Pending CN101759751A (en) | 2008-11-28 | 2008-11-28 | Ginsenoside Rg 1 containing ginsenoside Re impurity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101759751A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102453072A (en) * | 2010-10-26 | 2012-05-16 | 中国医学科学院药物研究所 | Preparation method of ginsenoside Rg1 |
| CN105477035A (en) * | 2016-01-12 | 2016-04-13 | 成都普瑞法科技开发有限公司 | Ginseng stem and leaf effective part and preparation method and application thereof |
| CN106589040A (en) * | 2016-12-28 | 2017-04-26 | 芜湖艾森格生物技术有限公司 | Method for separating panaxtrol saponin Rg1 and Re from panaxadiol saponin |
-
2008
- 2008-11-28 CN CN200810227642A patent/CN101759751A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102453072A (en) * | 2010-10-26 | 2012-05-16 | 中国医学科学院药物研究所 | Preparation method of ginsenoside Rg1 |
| CN105477035A (en) * | 2016-01-12 | 2016-04-13 | 成都普瑞法科技开发有限公司 | Ginseng stem and leaf effective part and preparation method and application thereof |
| CN106589040A (en) * | 2016-12-28 | 2017-04-26 | 芜湖艾森格生物技术有限公司 | Method for separating panaxtrol saponin Rg1 and Re from panaxadiol saponin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101311160B (en) | Method for preparing red sage root salviandic acid A | |
| CN101230003B (en) | Preparation method of salvia miltiorrhiza tanshinoate A | |
| CN108530430B (en) | Ester type catechin pyrrolidine alkaloid and preparation method and application thereof | |
| CN105250366B (en) | Dracocephalum moldavica extract and preparation method and application thereof | |
| CN104435034B (en) | A kind of arasaponin and preparation method thereof | |
| WO2018133563A1 (en) | Panax plant extract and pharmaceutical composition and use thereof | |
| CN108210566A (en) | A kind of limonin extract is preparing the application in treating diabetes medicament | |
| CN101006984B (en) | An injection preparation containing salvianolic acid A and extract of panax natoginseng, and its preparation method and application | |
| CN101759672B (en) | Salvianolic acid B in radix salviae miltiorrhizae | |
| CN101759751A (en) | Ginsenoside Rg 1 containing ginsenoside Re impurity | |
| CN101597314B (en) | Preparation method of ginsenoside Rg1 | |
| CN101390871B (en) | Ginsenoside Rb1 containing impurity ginsenoside Rd | |
| CN101006975B (en) | An oral medicine preparation containing salvianolic acid A and extract of panax natoginseng, and its preparation method and application | |
| CN101445544B (en) | Method for preparing ginsenoside Rb<1> | |
| CN101584743A (en) | Method for preparing Chinese traditional medicinal compound salvia miltiorrhiza preparation for curing cardiovascular and cerebrovascular diseases | |
| CN102085206B (en) | Medicinal composition | |
| CN1994277B (en) | Solid preparation of salvianolic acid A of red sage root and preparation process thereof | |
| CN101390870A (en) | Ginsenoside Rb1 containing impurity ginsenoside Rc | |
| CN103919759B (en) | A kind of containing danshensu sodium, the pharmaceutical composition of salvia miltiorrhiza tanshinoate F and preparation thereof | |
| CN101759752A (en) | Ginsenoside Rg 1 containing ginsenoside Rg 2 impurity | |
| CN102086223B (en) | Method for preparing ginsenoside Rg1 | |
| CN101696166B (en) | Preparation method for danshen root salvianolic acid A | |
| CN101392013A (en) | Ginsenoside Rb1 containing impurity ginsenoside Rh1 | |
| CN101759749A (en) | Ginsenoside Rg 1 containing ginsenoside Rf and/or pseudo-ginsenoside F11 impurity | |
| CN101019824B (en) | Preparation method of oral medicine composition containing salvianolic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100630 |